MAP2K7 and melanoma: Therefore, we analyzed the efficacy of MI-181 in a panel of melanoma cell lines with defined genetic backgrounds including BRAFV600E and NRASQ61L mutations and varied sensitivities to Vemurafenib (BRAF inhibitor) and Trametinib (MEK inhibitor), which are currently used to treat BRAFV600E melanomas43,44 (Figure 7c).